Tag Archives: NASDAQ:BOLD

Audentes Therapeutics (BOLD) Received its Third Buy in a Row

After Wedbush and Mizuho Securities gave Audentes Therapeutics (NASDAQ: BOLD) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Ritu Baral maintained a Buy rating on Audentes Therapeutics today. The company’s shares

Analysts Offer Insights on Healthcare Companies: Audentes Therapeutics (NASDAQ: BOLD) and Constellation Pharmaceuticals Inc (NASDAQ: CNST)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Audentes Therapeutics (BOLD – Research Report) and Constellation Pharmaceuticals Inc (CNST – Research Report) with bullish sentiments. Audentes Therapeutics (BOLD) In a

Mizuho Securities Sticks to Its Buy Rating for Audentes Therapeutics (BOLD)

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $45. The company’s shares closed yesterday at $27.77. Yang noted: “We believe this event

Audentes Therapeutics (BOLD) Receives a Hold from William Blair

In a report released yesterday, Raju Prasad from William Blair maintained a Hold rating on Audentes Therapeutics (BOLD – Research Report). The company’s shares closed yesterday at $27.77. According to TipRanks.com, Prasad is a 5-star analyst with an average return

Audentes Therapeutics (BOLD) Receives a Buy from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $45. The company’s shares opened today at $24.79. Yang commented: “We spoke with management

Audentes Therapeutics (BOLD) Receives a Rating Update from a Top Analyst

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Audentes Therapeutics (BOLD – Research Report) yesterday. The company’s shares closed yesterday at $24.80. According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.3%